Welcome to our dedicated page for Ventyx Biosciences SEC filings (Ticker: VTYX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ventyx Biosciences, Inc. (VTYX) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, alongside AI-generated summaries. Ventyx is a clinical-stage biopharmaceutical company listed on The Nasdaq Global Select Market under the symbol VTYX, as noted in its Form 8-K filings, and is therefore required to file periodic and current reports under the Securities Exchange Act of 1934.
Through this page, readers can review Ventyx’s Forms 10-K and 10-Q, which describe its business focus on oral small-molecule therapies for autoimmune, inflammatory, cardiovascular and neurodegenerative diseases, and provide details on its NLRP3 inhibitor programs (VTX2735 and VTX3232) and inflammatory bowel disease portfolio (tamuzimod/VTX002 and VTX958). Current reports on Form 8-K referenced in the input include announcements of quarterly financial results and top-line Phase 2 clinical data, such as the October 22, 2025 filing describing VTX3232 Phase 2 results in obesity and cardiovascular risk factors and the November 6, 2025 filing furnishing third-quarter financial results.
AI-powered tools on Stock Titan can help explain the key points in lengthy filings, such as risk factor sections, clinical development updates, and discussions of cash runway and operating plans. Users can also monitor 8-K filings related to material events, including the joint press release with Eli Lilly and Company announcing a definitive agreement for Lilly to acquire Ventyx in an all-cash transaction, subject to stockholder and regulatory approvals.
In addition, this page can surface Forms 3, 4 and 5 that report transactions in VTYX securities by directors and officers, as referenced generally in Ventyx’s proxy and ownership discussions. Real-time updates from EDGAR combined with AI summaries allow investors to quickly understand how new filings may relate to Ventyx’s clinical-stage pipeline, financial condition and the progress of its proposed acquisition by Eli Lilly and Company.
Ventyx Biosciences, Inc. has been acquired by Eli Lilly and Company through a merger in which each share of Ventyx common stock was converted into the right to receive $14.00 per share in cash, subject to tax withholding. A major shareholder, Somasundaram Subramaniam, reports that, as a result, he no longer beneficially owns any Ventyx securities.
Before the merger, shares held through NSV Partners III, L.P. and New Science Ventures, LLC were distributed on a pro rata basis for no consideration. Following the merger’s effective time, all stock options held by the reporting person were canceled and converted into cash based on the $14.00 merger consideration above the applicable exercise prices.
Ventyx Biosciences has been acquired by Eli Lilly and Company, with Ventyx becoming a wholly owned subsidiary through a merger. Under the merger agreement, each share of Ventyx common stock was converted into the right to receive $14.00 in cash per share, without interest, at the merger’s effective time.
Senior VP of Finance Roy Gonzales reported dispositions to the issuer of multiple stock option awards covering an aggregate of 281,700 options and 5,313 common shares. In-the-money options were automatically cancelled and converted into a cash payment equal to the spread over the $14.00 per-share price, while underwater options were cancelled for no consideration, in each case pursuant to the merger agreement.
Ventyx Biosciences, Inc. became a wholly owned subsidiary of Eli Lilly and Company through a merger in which Eli Lilly’s RYLS Merger Corporation combined with Ventyx. At the effective time of the merger, each Ventyx share was converted into the right to receive $14.00 in cash per share, subject to the merger agreement terms.
A fund group referred to as the NSV Funds disposed of an aggregate 3,337,495 shares of common stock, held by NSV Investments I, L.P., NSV Partners III, L.P., New Science Ventures, LLC, and NSV Partners II, LLC, in exchange for this cash consideration. Director Subramaniam Somu may be deemed to have voting and dispositive power over these entities but disclaims beneficial ownership except for his pecuniary interest.
Several stock options held by the reporting person were also affected. In-the-money options were automatically cancelled and converted into a cash payment equal to the number of option shares multiplied by the excess of the $14.00 per share price over the option exercise price, less withholding taxes. Fully vested options with exercise prices above $14.00 per share were cancelled for no consideration.
Ventyx Biosciences director William Richard White reported the disposition of multiple stock options on March 4, 2026 in transactions with the issuer. The footnotes explain these were mechanical changes tied to Ventyx’s merger with Eli Lilly and Company, which made Ventyx a wholly owned subsidiary.
At the merger’s effective time, options with exercise prices at or below $14.00 per share were automatically cancelled and converted into a cash right based on the spread to the merger per-share price. Fully vested options with exercise prices above that per-share price were automatically cancelled for no consideration.
Moore Matthew Richard reported disposition transactions in this Form 4 filing.
Ventyx Biosciences Chief Operating Officer Matthew Richard Moore reported the cancellation of two stock option awards in connection with the company’s merger with Eli Lilly and Company. A Lilly subsidiary merged into Ventyx, leaving Ventyx as a wholly owned subsidiary of Lilly.
At the merger’s effective time, options covering 145,000 and 320,000 shares of Ventyx common stock were automatically canceled. Because each option had an exercise price per share less than or equal to $14.00, they were converted into a right to receive cash equal to the number of shares underlying each option multiplied by the excess, if any, of $14.00 over the option’s exercise price, less applicable taxes.
Ventyx Biosciences director Onaiza Cadoret-Manier reported the disposition of stock options to the company in connection with its merger with Eli Lilly and Company. The filing explains that RYLS Merger Corporation merged into Ventyx, which survived the merger and became a wholly owned subsidiary of Eli Lilly.
At the effective time of the merger, any reported option with an exercise price per share less than or equal to the $14.00 per share cash merger price was automatically cancelled and converted into a right to receive cash equal to the number of option shares multiplied by the excess of $14.00 over the option’s exercise price, less applicable withholding taxes. Options with an exercise price per share greater than $14.00 were automatically cancelled at the effective time for no consideration.
Ventyx Biosciences director Allison Hulme reported the disposition of stock options in connection with the company’s merger with Eli Lilly. At the merger’s effective time, vested options with exercise prices at or below $14.00 per share were automatically cancelled and converted into cash equal to the per-share merger price minus the option exercise price. Fully vested options with exercise prices above $14.00 per share were automatically cancelled for no consideration under the merger agreement.